Towards a better diagnosis and treatment of dementia: Identifying common and distinct neuropathological mechanisms in Alzheimer's and vascular dementia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39999928/
Alzheimer's disease (AD) and vascular dementia (VaD) together contribute to almost 90 % of all dementia cases leading to major health challenges of our time with a substantial global socioeconomic...
Alzheimer’s and vascular dementia share key pathomechanisms, including endothelial damage, BBB breakdown, oxidative stress, and inflammation. Understanding these overlaps may improve diagnostics and reveal therapeutic targets for both dementia types.
Behavioural and psychological symptoms of people with dementia in acute hospital settings: a systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39888603/
Healthcare systems should implement tailored approaches for managing BPSD in acute hospitals, enhance staff training, improve caregiver communication, and develop integrated discharge plans.
BPSD affects 60% of older inpatients with dementia in acute hospitals, leading to increased interventions and poor outcomes. Common symptoms include agitation, sleep, and eating issues. Better staff training and discharge planning are needed.
Emerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer's Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39623197/
Psychosis and agitation are among the most distressing neuropsychiatric symptoms (NPSs) of Alzheimer's disease (AD), linked to faster disease progression and earlier admission to nursing homes. While nonpharmacological treatments may...
Psychosis and agitation in Alzheimer's disease require effective treatments. Promising drugs in phase 3 trials include xanomeline-trospium, dextromethorphan-bupropion, and dexmedetomidine, with biomarker-driven strategies suggested for optimizing drug development.
A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39344050/
Approval by the Food and Drug Administration (FDA) of brexpiprazole for the treatment of agitation in dementia due to AD is an important milestone and regulatory precedent. This is the...
Brexpiprazole, FDA-approved for agitation in Alzheimer's dementia, demonstrates efficacy and safety in Phase 2/3 trials. It shows significant agitation reduction and comparable safety to placebo, with post-marketing surveillance crucial.
Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39369280/
Brexpiprazole treatment for 10 weeks improved agitation in Alzheimer's dementia. The efficacy of brexpiprazole 1 mg/day has been confirmed for the first time. The incidence of adverse events was higher...
Brexpiprazole (1 mg and 2 mg/day) significantly improved agitation in Alzheimer's dementia over 10 weeks, with higher adverse event rates than prior studies, but was generally well tolerated.